HIV — The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study
Citation(s)
A Phase 1 Pharmacokinetic Study to Assess the Steady State Pharmacokinetic Profile and Short Term Safety of Maraviroc Dosed With Darunavir/Ritonavir All Once Daily, With and Without Nucleoside Analogues, in HIV-1 Infected Subjects